{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:45:06Z","timestamp":1791726306006,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["Consejer\u00eda de Educaci\u00f3n, Universidades e Investigaci\u00f3n del Gobierno Vasco (GIC15 IT-990-16)"],"award-info":[{"award-number":["Consejer\u00eda de Educaci\u00f3n, Universidades e Investigaci\u00f3n del Gobierno Vasco (GIC15 IT-990-16)"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to assess the <jats:italic>in vitro<\/jats:italic> activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of <jats:italic>Candida<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 <jats:italic>Candida albicans<\/jats:italic>, 108 <jats:italic>Candida parapsilosis<\/jats:italic>, 60 <jats:italic>Candida glabrata<\/jats:italic>, 40 <jats:italic>Candida tropicalis<\/jats:italic>, 29 <jats:italic>Candida krusei<\/jats:italic>, 20 <jats:italic>Candida orthopsilosis<\/jats:italic>, 6 <jats:italic>Candida guilliermondii<\/jats:italic>, 2 <jats:italic>Candida famata<\/jats:italic>, 2 <jats:italic>Candida lusitaniae<\/jats:italic>, and 1 isolate each of <jats:italic>Candida bracarensis, Candida catenulata<\/jats:italic>, <jats:italic>Candida dubliniensis<\/jats:italic>, and <jats:italic>Candida kefyr<\/jats:italic>. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 <jats:italic>Candida auris<\/jats:italic> from different clinical specimens were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ibrexafungerp MICs ranged from 0.016 to \u22658 mg\/L. The lowest ibrexafungerp MICs were observed for <jats:italic>C. albicans<\/jats:italic> (geometric MIC 0.062 mg\/L, MIC range 0.016\u20130.5 mg\/L) and the highest ibrexafungerp MICs were observed for <jats:italic>C. tropicalis<\/jats:italic> (geometric MIC 0.517 mg\/L, MIC range 0.06\u2013\u22658 mg\/L). Modal MICs\/MIC<jats:sub>50<\/jats:sub>s (mg\/L) against <jats:italic>Candida<\/jats:italic> spp. were 0.125\/0.06 for <jats:italic>C. albicans<\/jats:italic>, 0.5\/0.5 for <jats:italic>C. parapsilosis<\/jats:italic>, 0.25\/0.25 for <jats:italic>C. glabrata<\/jats:italic>, 0.5\/0.5 for <jats:italic>C. tropicalis<\/jats:italic>, 1\/1 for <jats:italic>C. krusei<\/jats:italic>, 4\/2 for <jats:italic>C. orthopsilosis<\/jats:italic>, and 0.5\/0.5 for <jats:italic>C. auris<\/jats:italic>. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16\/434 (3.7%) isolates: 11 (4.6%) <jats:italic>C. parapsilosis<\/jats:italic>, 4 (5%) <jats:italic>C. glabrata<\/jats:italic>, and 1 (2.5%) <jats:italic>C. tropicalis<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ibrexafungerp showed a potent <jats:italic>in vitro<\/jats:italic> activity against <jats:italic>Candida<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.906563","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:48:52Z","timestamp":1652683732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Guillermo","family":"Quind\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Miranda-Cadena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"San-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Linares-Sicilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Tortorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Prigitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matxalen","family":"Vidal-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Marcos-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Sanchez-Reus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Machuca-B\u00e1rcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Antonio","family":"Rodr\u00edguez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Mart\u00edn-Mazuelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Castro-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"L\u00f3pez-Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Ruiz-Gait\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Fernandez-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damaris","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Capilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rezusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Guarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ezpeleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Jauregizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Eraso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing Echinocandin Resistance in Candida Glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to Interpret MICs of Antifungal Compounds According to the Revised Clinical Breakpoints V. 10.0 European Committee on Antimicrobial Susceptibility Testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B3","unstructured":"ArendrupM. C.\n            MeletiadisJ.\n            MoutonJ. W.\n            LagrouK.\n            HamalP.\n            GuineaJ.\n          EUCAST Definitive Document E.DEF 7.3.2 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment","author":"Arendrup","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00435-17","article-title":"In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, Against Clinical Isolates of Candida Auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A Novel Oral Glucan Synthase Inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02644-16","article-title":"Molecular Confirmation of the Relationship Between Candida Guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility","volume":"61","author":"Dudiuk","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory Variability of Caspofungin MICs for Candida Spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","unstructured":"European Committee on Antimicrobial Susceptibility Testing Breakpoint. Antifungal Agents: Tables for Interpretation of MICs Version 10.02020"},{"key":"B10","unstructured":"MIC and Zone Diameter Distributions and ECOFFs2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"iv48","DOI":"10.1093\/jac\/dkz287","article-title":"Species Distribution and Antifungal Susceptibility of Invasive Candida Isolates From Canadian Hospitals: Results of the CANWARD 2011-16 Study","volume":"74","author":"Fuller","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.642358","article-title":"And Ghannoum, M","volume":"11","author":"Gamal","year":"2021","journal-title":"A Front. Cell Infect. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1128\/AAC.00262-08","article-title":"A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida Parapsilosis, Candida Orthopsilosis, and Candida Metapsilosis Accounts for Reduced Echinocandin Susceptibility","volume":"52","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2015.01.010","article-title":"Comparison of the In Vitro Activity of Echinocandins Against Candida Albicans, Candida Dubliniensis, and Candida Africana by Time-Kill Curves","volume":"82","author":"Gil-Alonso","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1128\/AAC.04474-14","article-title":"In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin Against Candida Glabrata, Candida Bracarensis, and Candida Nivariensis Evaluated by Time-Kill Studies","volume":"59","author":"Gil-Alonso","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency Against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates","volume":"58","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e00833","DOI":"10.1128\/AAC.00833-17","article-title":"De Novo Acquisition of Resistance to SCY-078 in Candida Glabrata Involves FKS Mutations That Both Overlap and Are Distinct From Those Conferring Echinocandin Resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16","article-title":"The Emerging Pathogen Candida Auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, A Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: A Prospective Multicenter Study Involving 2,441 Patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The Novel Oral Glucan Synthase Inhibitor SCY-078 Shows In Vitro Activity Against Sessile and Planktonic Candida Spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"140.e1","DOI":"10.1016\/j.cmi.2021.09.030","article-title":"In Vitro Activity of Ibrexafungerp Against Candida Species Isolated From Blood Cultures. Determination of Wild-Type Populations Using the EUCAST Method","volume":"28","author":"Mesquida","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"915.e5","DOI":"10.1016\/j.cmi.2021.02.006","article-title":"In Vitro Activity of Ibrexafungerp and Comparators Against Candida Albicans Genotypes From Vaginal Samples and Blood Cultures","volume":"27","author":"Mesquida","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/jac\/dkr298","article-title":"Prevalence and Antifungal Susceptibility Patterns of New Cryptic Species Inside the Species Complexes Candida Parapsilosis and Candida Glabrata Among Blood Isolates From a Spanish Tertiary Hospital","volume":"66","author":"Miranda-Zapico","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01692-19","article-title":"In Vitro Activity of Ibrexafungerp, A Novel Glucan Synthase Inhibitor Against Candida Glabrata Isolates With FKS Mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/jac\/dks019","article-title":"Epidemiology, Species Distribution, and In Vitro Antifungal Susceptibility of Fungaemia in a Spanish Multicentre Prospective Survey","volume":"67","author":"Pem\u00e1n","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1128\/JCM.06112-11.O","article-title":"Frequency of Decreased Susceptibility and Resistance to Echinocandins Among Fluconazole-Resistant Bloodstream Isolates of Candida Glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, A New Oral Glucan Synthase Inhibitor, Tested Against Candida Spp. By Two International Methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17","article-title":"Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 Against Wild-Type and Echinocandin-Resistant Strains of Candida Species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1128\/AAC.03255-15","article-title":"The Role of FKS Mutations in C. Glabrata: MIC Values, Echinocandin Resistance and Multidrug Resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.riam.2013.10.001","article-title":"Epidemiology of Candidaemia and Invasive Candidiasis. A Changing Face","volume":"31","author":"Quind\u00f3s","year":"2014","journal-title":"Rev. Iberoam. Micol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10123-018-0014-1","article-title":"The Continuous Changes in the Aetiology and Epidemiology of Invasive Candidiasis: From Familiar Candida Albicans to Multiresistant Candida Auris","volume":"21","author":"Quind\u00f3s","year":"2018","journal-title":"Int. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2019.02.005","article-title":"Outbreak of Candida Auris in Spain: A Comparison of Antifungal Activity by Three Methods With Published Data","volume":"53","author":"Ruiz-Gait\u00e1n","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.riam.2016.11.002","article-title":"Nosocomial Fungemia by Candida Auris: First Four Reported Cases in Continental Europe","volume":"34","author":"Ruiz-Gait\u00e1n","year":"2017","journal-title":"Rev. Iberoam. Micol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/myc.12781","article-title":"An Outbreak Due to Candida Auris With Prolonged Colonisation and Candidaemia in a Tertiary Care European Hospital","volume":"61","author":"Ruiz-Gait\u00e1n","year":"2018","journal-title":"Mycoses"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal Activity of SCY-078 and Standard Antifungal Agents Against 178 Clinical Isolates of Resistant and Susceptible Candida Species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)","volume":"750","author":"Schwebke","year":"2021","journal-title":"Clin. Infect. Dis. Ciab."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 Is Fungicidal Against Candida Species in Time-Kill Studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1128\/AAC.00136-13","article-title":"Caspofungin MICs Correlate With Treatment Outcomes Among Patients With Candida Glabrata Invasive Candidiasis and Prior Echinocandin Exposure","volume":"57","author":"Shields","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and Safety of Oral Ibrexafungerp for the Treatment of Acute Vulvovaginal Candidiasis: A\u2009Global Phase 3, Randomised, Placebo-Controlled Superiority Study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: A Phase 2 Study of Oral Ibrexafungerp (SCY-078) Following Initial Echinocandin Therapy in Non-Neutropenic Patients With Invasive Candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.2147\/IDR.S274872","article-title":"Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches","volume":"14","author":"Tortorano","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"B44","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10096-016-2841-3","article-title":"Epidemiology and Reporting of Candidaemia in Belgium: A Multi-Centre Study","volume":"36","author":"Trouv\u00e9","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab444","article-title":"Antifungal Susceptibility Testing: A Primer for Clinicians","volume":"8","author":"Wiederhold","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral Glucan Synthase Inhibitor SCY-078 Is Effective in an Experimental Murine Model of Invasive Candidiasis Caused by WT and Echinocandin-Resistant Candida Glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02694-20","article-title":"Ibrexafungerp Demonstrates In Vitro Activity Against Fluconazole-Resistant Candida Auris and In Vivo Efficacy With Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis","volume":"65","author":"Wiederhold","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, A Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J. Clin. Pharmacol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.906563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:48:56Z","timestamp":1652683736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.906563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":48,"alternative-id":["10.3389\/fcimb.2022.906563"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.906563","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"906563"}}